{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:01:04Z","timestamp":1791460864286,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["AI036214"],"award-info":[{"award-number":["AI036214"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Korea HIV\/AIDS Cohort Study","award":["2019-ER5101-00"],"award-info":[{"award-number":["2019-ER5101-00"]}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2019K1A5A2077463"],"award-info":[{"award-number":["2019K1A5A2077463"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["FY2019"],"award-info":[{"award-number":["FY2019"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ministry of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In February 2018, the Ministry of Food and Drug Safety in Korea approved tenofovir disoproxil fumarate and emtricitabine (TDF\/FTC) co-formulate for use in pre-exposure prophylaxis (PrEP) for the prevention of human immunodeficiency virus (HIV) infection. This study aimed to estimate the cost-effectiveness of PrEP in men who have sex with men (MSM), a major risk group emerging in Korea. A dynamic compartmental model was developed for HIV transmission and progression in MSM aged 15\u201364\u00a0years. With a combined model including economic analysis, we estimated averted HIV infections, changes in HIV prevalence, discounted costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). PrEP was evaluated in both the general MSM and high-risk MSM populations and was assumed to reduce infection risk by 80%. Implementing PrEP in all MSM would avert 75.2% HIV infections and facilitate a gain of 37,372 QALYs at a cost of $274,822 per QALY gained over 20\u00a0years relative to the status quo. Initiating PrEP in high-risk MSM with an average of eight partners per year (around 20% of MSM) would improve the cost-effectiveness, averting 78.0% HIV infections and add 29,242 QALYs at a cost of $51,597 per QALY gained, which is within the willingness-to-pay threshold for Korea of $56,000\/QALY gained. This result was highly sensitive to annual PrEP costs, quality-of-life for people who are on PrEP, and initial HIV prevalence. Initiating PrEP in a larger proportion of MSM in Korea would prevent more HIV infections, but at an increasing cost per QALY gained. Focusing PrEP on higher risk MSM and any reduction in PrEP cost would improve cost-effectiveness.<\/jats:p>","DOI":"10.1038\/s41598-020-71565-y","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T10:04:10Z","timestamp":1599127450000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Cost-effectiveness analysis of pre-exposure prophylaxis for the prevention of HIV in men who have sex with men in South Korea: a mathematical modelling study"],"prefix":"10.1038","volume":"10","author":[{"given":"Heun","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyeon","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woonji","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Hyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye","family":"Seong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Young","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Jin","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam Su","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Sup","family":"Yeom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee-Dae","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davey M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeehyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Yong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"key":"71565_CR1","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"363","author":"RM Grant","year":"2010","unstructured":"Grant, R. M. et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363, 2587\u20132599 (2010).","journal-title":"N. Engl. J. Med."},{"key":"71565_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1126\/scitranslmed.3004006","volume":"4","author":"PL Anderson","year":"2012","unstructured":"Anderson, P. L. et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci. Transl. Med. 4, 151 (2012).","journal-title":"Sci. Transl. Med."},{"key":"71565_CR3","first-page":"65","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","unstructured":"Centers for Disease Control and Prevention (CDC). Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb. Mortal Wkly. Rep. 60, 65\u201368 (2011).","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"71565_CR4","first-page":"586","volume":"61","author":"Centers for Disease Control and Prevention (CDC)","year":"2012","unstructured":"Centers for Disease Control and Prevention (CDC). Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR Morb. Mortal Wkly. Rep. 61, 586\u2013589 (2012).","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"71565_CR5","first-page":"463","volume":"62","author":"Centers for Disease Control and Prevention (CDC)","year":"2013","unstructured":"Centers for Disease Control and Prevention (CDC). Update to interim guidance for preexposure prophylaxis (PrEP) for the prevention of HIV infection: PrEP for injecting drug users. MMWR Morb. Mortal Wkly. Rep. 62, 463\u2013465 (2013).","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"71565_CR6","doi-asserted-by":"publisher","first-page":"778","DOI":"10.7326\/0003-4819-153-12-201012210-00004","volume":"153","author":"EF Long","year":"2010","unstructured":"Long, E. F., Brandeau, M. L. & Owens, D. K. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann. Intern. Med. 153, 778\u2013789 (2010).","journal-title":"Ann. Intern. Med."},{"key":"71565_CR7","doi-asserted-by":"publisher","first-page":"e90080","DOI":"10.1371\/journal.pone.0090080","volume":"9","author":"SB Kim","year":"2014","unstructured":"Kim, S. B. et al. Mathematical modeling of HIV prevention measures including pre-exposure prophylaxis on HIV incidence in South Korea. PLoS ONE 9, e90080 (2014).","journal-title":"PLoS ONE"},{"key":"71565_CR8","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.phrp.2012.07.001","volume":"3","author":"A Sohn","year":"2012","unstructured":"Sohn, A. & Cho, B. Knowledge, attitudes, and sexual behaviors in HIV\/AIDS and predictors affecting condom use among men who have sex with men in South Korea. Osong Public Health Res. Persp. 3, 156\u2013164 (2012).","journal-title":"Osong Public Health Res. Persp."},{"key":"71565_CR9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3961\/jpmph.2012.45.3.156","volume":"45","author":"M Jung","year":"2012","unstructured":"Jung, M., Lee, J., Kwon, D. S. & Park, B. J. Comparison of sexual risky factors of men who have sex with men and sex-buying men as groups vulnerable to sexually transmitted diseases. J. Prev. Med. Public Health 45, 156\u2013163 (2012).","journal-title":"J. Prev. Med. Public Health"},{"key":"71565_CR10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s11904-014-0201-4","volume":"11","author":"SP Suguimoto","year":"2014","unstructured":"Suguimoto, S. P. et al. Changing patterns of HIV epidemic in 30 years in East Asia. Curr. HIV\/AIDS Rep. 11, 134\u2013145 (2014).","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"71565_CR11","unstructured":"Korea Centers for Disease Control and Prevention Annual Report on the Notified HIV\/AIDS in Korea 2017 (2018). https:\/\/www.cdc.go.kr\/menu.es?mid=a20301070305. Accessed 11 October 2018."},{"key":"71565_CR12","unstructured":"Korea Centers for Disease Control and Prevention Annual Report on the Notified HIV\/AIDS in Korea 2018 (2019). https:\/\/www.cdc.go.kr\/menu.es?mid=a20301070305. Accessed 5 October 2019."},{"key":"71565_CR13","unstructured":"Korean Statistical Information Service Vital Statistics of Korea (2016). https:\/\/kosis.kr\/statHtml\/statHtml.do?orgId=101&tblId=DT_1IN1503&conn_path=I2. Accessed 21 November 2017."},{"key":"71565_CR14","unstructured":"Health Insurance Review & Assessment Service Fee schedule (2016). https:\/\/www.hira.or.kr\/rd\/insuadtcrtr\/InsuAdtCrtrList.do?pgmid=HIRAA030069000400. Accessed 3 May 2018."},{"key":"71565_CR15","unstructured":"Korean Statistical Information Service Benefits by Classification of Disease Categories (2015). https:\/\/kosis.kr\/statHtml\/statHtml.do?orgId=350&tblId=TX_35001_A061&conn_path=I2. Accessed 15 Jan 2018."},{"key":"71565_CR16","unstructured":"Korea Centers for Disease Control and Prevention National Survey on the Sexual Consciousness (2015). https:\/\/www.ndsl.kr\/ndsl\/search\/detail\/report\/reportSearchResultDetail.do?cn=TRKO201600015992. Accessed 2 October 2017."},{"key":"71565_CR17","unstructured":"Korea Centers for Disease Control and Prevention Utilization of Health Care Services among people with HIV infection (2015). https:\/\/www.ndsl.kr\/ndsl\/search\/detail\/report\/reportSearchResultDetail.do?cn=TRKO201600015993. Accessed 20 March 2018."},{"key":"71565_CR18","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.phrp.2015.06.003","volume":"6","author":"A Sohn","year":"2015","unstructured":"Sohn, A., Cho, B. & Kennedy, H. A. Identifying barriers to human immunodeficiency virus testing for men who have sex with men in South Korea. Osong Public Health Res. Persp. 6, 192\u2013200 (2015).","journal-title":"Osong Public Health Res. Persp."},{"key":"71565_CR19","doi-asserted-by":"publisher","first-page":"5402","DOI":"10.1016\/j.vaccine.2009.06.063","volume":"27","author":"EF Long","year":"2009","unstructured":"Long, E. F., Brandeau, M. L. & Owens, D. K. Potential population health outcomes and expenditures of HIV vaccination strategies in the United States. Vaccine 27, 5402\u20135410 (2009).","journal-title":"Vaccine"},{"key":"71565_CR20","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1097\/00002030-200305020-00012","volume":"17","author":"M Xiridou","year":"2003","unstructured":"Xiridou, M., Geskus, R., De Wit, J., Coutinho, R. & Kretzschmar, M. The contribution of steady and casual partnerships to the incidence of HIV infection among homosexual men in Amsterdam. AIDS 17, 1029\u20131038 (2003).","journal-title":"AIDS"},{"key":"71565_CR21","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1086\/512816","volume":"44","author":"AW McCormick","year":"2007","unstructured":"McCormick, A. W. et al. The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin. Infect. Dis. 44, 1115\u20131122 (2007).","journal-title":"Clin. Infect. Dis."},{"key":"71565_CR22","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1086\/429411","volume":"191","author":"MJ Wawer","year":"2005","unstructured":"Wawer, M. J. et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J. Infect. Dis. 191, 1403\u20131409 (2005).","journal-title":"J. Infect. Dis."},{"key":"71565_CR23","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1097\/QAD.0b013e328133f285","volume":"21","author":"M May","year":"2007","unstructured":"May, M. et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: Collaborative analysis of prospective studies. AIDS 21, 1185\u20131197 (2007).","journal-title":"AIDS"},{"key":"71565_CR24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(08)61113-7","volume":"372","author":"RS Hogg","year":"2008","unstructured":"Hogg, R. S. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. Lancet 372, 293\u2013299 (2008).","journal-title":"Lancet"},{"key":"71565_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/jama.2018.8431","volume":"320","author":"MS Saag","year":"2018","unstructured":"Saag, M. S. et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the international antiviral society-USA Panel. JAMA 320, 379\u2013396 (2018).","journal-title":"JAMA"},{"key":"71565_CR26","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1056\/NEJMsa042657","volume":"352","author":"GD Sanders","year":"2005","unstructured":"Sanders, G. D. et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N. Engl. J. Med. 352, 570\u2013585 (2005).","journal-title":"N. Engl. J. Med."},{"key":"71565_CR27","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1056\/NEJMoa1600693","volume":"375","author":"MS Cohen","year":"2016","unstructured":"Cohen, M. S. et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N. Engl. J. Med. 375, 830\u2013839 (2016).","journal-title":"N. Engl. J. Med."},{"key":"71565_CR28","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(08)61115-0","volume":"372","author":"DP Wilson","year":"2008","unstructured":"Wilson, D. P., Law, M. G., Grulich, A. E., Cooper, D. A. & Kaldor, J. M. Relation between HIV viral load and infectiousness: A model-based analysis. Lancet 372, 314\u2013320 (2008).","journal-title":"Lancet"},{"key":"71565_CR29","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/QAI.0b013e3181ee4c62","volume":"55","author":"CD Rose","year":"2010","unstructured":"Rose, C. D. et al. HIV intervention for providers study: A randomized controlled trial of a clinician-delivered HIV risk-reduction intervention for HIV-positive people. J. Acquir. Immune Defic. Syndr. 55, 572\u2013581 (2010).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"71565_CR30","doi-asserted-by":"publisher","first-page":"541","DOI":"10.7326\/0003-4819-156-8-201204170-00001","volume":"156","author":"JL Juusola","year":"2012","unstructured":"Juusola, J. L., Brandeau, M. L., Owens, D. K. & Bendavid, E. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann. Intern. Med. 156, 541\u2013550 (2012).","journal-title":"Ann. Intern. Med."},{"key":"71565_CR31","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.3346\/jkms.2018.33.e91","volume":"33","author":"HH Chang","year":"2018","unstructured":"Chang, H. H. et al. Awareness and acceptance of HIV pre-exposure prophylaxis among medical personnel and men who have sex with men in Korea. J. Korean Med. Sci. 33, e91 (2018).","journal-title":"J. Korean Med. Sci."},{"key":"71565_CR32","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3947\/ic.2017.49.3.243","volume":"49","author":"The Korean Society for AIDS","year":"2017","unstructured":"The Korean Society for AIDS. Summary of guidelines for the use of pre-exposure prophylaxis for HIV in Korea. Infect. Chemother. 49, 243\u2013246 (2017).","journal-title":"Infect. Chemother."},{"key":"71565_CR33","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1097\/QAD.0000000000001145","volume":"30","author":"VA Fonner","year":"2016","unstructured":"Fonner, V. A. et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS 30, 1973\u20131983 (2016).","journal-title":"AIDS"},{"key":"71565_CR34","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/cid\/civ778","volume":"61","author":"JE Volk","year":"2015","unstructured":"Volk, J. E. et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin. Infect. Dis. 61, 1601\u20131603 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"71565_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","volume":"387","author":"S McCormack","year":"2016","unstructured":"McCormack, S. et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): Effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 387, 53\u201360 (2016).","journal-title":"Lancet"},{"key":"71565_CR36","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1089\/apc.2010.0173","volume":"24","author":"EA Barash","year":"2010","unstructured":"Barash, E. A. & Golden, M. Awareness and use of HIV pre-exposure prophylaxis among attendees of a seattle gay pride event and sexually transmitted disease clinic. AIDS Patient Care STDS 24, 689\u2013691 (2010).","journal-title":"AIDS Patient Care STDS"},{"key":"71565_CR37","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/QAI.0b013e3181e19a54","volume":"54","author":"SA Golub","year":"2010","unstructured":"Golub, S. A., Kowalczyk, W., Weinberger, C. L. & Parsons, J. T. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J. Acquir. Immune Defic. Syndr. 54, 548\u2013555 (2010).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"71565_CR38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/QAI.0b013e31815e4041","volume":"47","author":"AY Liu","year":"2008","unstructured":"Liu, A. Y. et al. Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J. Acquir. Immune Defic. Syndr. 47, 241\u2013247 (2008).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"71565_CR39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/QAI.0b013e31818d5a27","volume":"50","author":"MJ Mimiaga","year":"2009","unstructured":"Mimiaga, M. J., Case, P., Johnson, C. V., Safren, S. A. & Mayer, K. H. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: Limited knowledge and experience but potential for increased utilization after education. J. Acquir. Immune Defic. Syndr. 50, 77\u201383 (2009).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"71565_CR40","unstructured":"Organization for Economic Co-operation and Development (OECD) Health expenditure and financing\u2014Korea (2015). https:\/\/stats.oecd.org\/Index.aspx?DataSetCode=SHA. Accessed 18 August 2018."},{"key":"71565_CR41","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/1471-2458-10-411","volume":"10","author":"JH Lee","year":"2010","unstructured":"Lee, J. H. et al. Increasing late diagnosis in HIV infection in South Korea: 2000\u20132007. BMC Public Health 10, 411 (2010).","journal-title":"BMC Public Health"},{"key":"71565_CR42","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jinf.2011.05.002","volume":"63","author":"PG Choe","year":"2011","unstructured":"Choe, P. G. et al. Late presentation of HIV disease and its associated factors among newly diagnosed patients before and after abolition of a government policy of mass mandatory screening. J. Infect. 63, 60\u201365 (2011).","journal-title":"J. Infect."},{"key":"71565_CR43","doi-asserted-by":"publisher","first-page":"e304","DOI":"10.3346\/jkms.2018.33.e304","volume":"33","author":"YH Lee","year":"2018","unstructured":"Lee, Y. H. et al. Cost-effectiveness of voluntary HIV testing strategies in a very low-prevalence country, the Republic of Korea. J. Korean Med. Sci. 33, e304 (2018).","journal-title":"J. Korean Med. Sci."},{"key":"71565_CR44","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1097\/QAD.0b013e32834d3cab","volume":"25","author":"SB Keller","year":"2011","unstructured":"Keller, S. B. & Smith, D. M. The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis. AIDS 25, 2308\u20132310 (2011).","journal-title":"AIDS"},{"key":"71565_CR45","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1097\/QAD.0000000000000460","volume":"28","author":"J Kessler","year":"2014","unstructured":"Kessler, J. et al. Evaluating the impact of prioritization of antiretroviral pre-exposure prophylaxis in New York. AIDS 28, 2683\u20132691 (2014).","journal-title":"AIDS"},{"key":"71565_CR46","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1097\/QAI.0000000000000987","volume":"72","author":"EL Ross","year":"2016","unstructured":"Ross, E. L., Cinti, S. K. & Hutton, D. W. Implementation and operational research: A cost-effective, clinically actionable strategy for targeting HIV preexposure prophylaxis to high-risk men who have sex with men. J. Acquir. Immune Defic. Syndr. 72, e61 (2016).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"71565_CR47","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1093\/cid\/cit946","volume":"58","author":"K Schneider","year":"2014","unstructured":"Schneider, K., Gray, R. T. & Wilson, D. P. A cost-effectiveness analysis of HIV preexposure prophylaxis for men who have sex with men in Australia. Clin. Infect. Dis. 58, 1027\u20131034 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"71565_CR48","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1473-3099(16)30311-5","volume":"16","author":"BE Nichols","year":"2016","unstructured":"Nichols, B. E., Boucher, C. A. B., van der Valk, M., Rijnders, B. J. A. & van de Vijver, D. Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: A mathematical modelling study. Lancet Infect. Dis. 16, 1423\u20131429 (2016).","journal-title":"Lancet Infect. Dis."},{"key":"71565_CR49","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","volume":"373","author":"JM Molina","year":"2015","unstructured":"Molina, J. M. et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N. Engl. J. Med. 373, 2237\u20132246 (2015).","journal-title":"N. Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71565-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71565-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71565-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T18:07:05Z","timestamp":1670350025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71565-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["71565"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-71565-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,3]]},"assertion":[{"value":"13 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14609"}}